Picture: Bayer AG

Bayer AG presents successor für CEO Baumann

The Supervisory Board of Bayer AG has appointed Roche Pharmaceuticals CEO Bill Anderson (56) as new Chairman of the Management Board of Bayer AG with effect from 1 June 2023.

Anderson will join the life sciences company based in Leverkusen, Germany, as a member of the Board of Management on 1 April 2023. Bayer's current CEO, Werner Baumann (60), will work closely with him to ensure a smooth transition before he retires at the end of May 2023 after 35 years of service at Bayer.

The chemical engineer Bill Anderson has held various leadership positions in the life sciences industry over the past 25 years. In 2019, he became CEO of Roche Pharmaceuticals. Based in Switzerland, he led a comprehensive transformation programme for the division that resulted in significant productivity gains and sales growth despite the substantial impact of patent losses. Prior to that, Anderson was CEO of biotech pioneer Genentech. Prior to that, Anderson held several senior positions in general management, product development and finance at Biogen and at technology and electronics company Raychem. Bill Anderson has lived in the United Kingdom, the Netherlands, Belgium and Switzerland, among other countries. In his new role, he will be based in Leverkusen, Germany.

The 56-year-old US-American holds a Bachelor of Science in Chemical Engineering from the University of Texas and a Master of Science in Chemical Engineering and Management from the Massachusetts Institute of Technology (MIT).

Picture: Bayer AG